Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pharmaceutical companies are eagerly pursuing GenAI products and use cases to generate value within their organisations. Many are heavily investing in consultants to help develop strategies and ...